With this new acquisition the Icare Group confirms its strategy of external growth and development of its service offer in a medical field deemed to be of strategic importance, given the evidence of the complementarity of the three structures to meet the needs of its clients and regulatory developments, in France and International.
\nICARE is an international group with 4 specialized subsidiaries: Laboratoire ICARE, ICARE Validation, Laboratoire ICARE SWITZERLAND (in Switzerland) and MEDLAB (in Brazil). Service provider, expert in contamination control for industrial health stakeholders, its main activity is to ensure the safety of health products in compliance with regulations.<\/p>\n
The group offers :<\/p>\n
\u2022 Life sciences (Medical Device and pharma Testing): laboratory analysis, microbiology, physical and chemical test results, characterization, tests on packaging\u2026
\n\u2022 Validation Qualification: Process, production and laboratory equipment, software, shipping validation, assistance in the formulation of strategies, drafting of protocols and reports, test performance\u2026
\n\u2022 Technical assistance: assistance and training programs related to regulatory requirements, technical assistance, regulatory assistance, and monitoring \u2026
\n\u2022 R&D: custom development of innovative processes and products, tailored test facility, optimization\u2026<\/p>\n
The laboratories LEMI and PHYCHER Bio d\u00e9veloppement round out this offer via the following services:<\/p>\n
\u2022 biological Risk Assessment (BRA)
\n\u2022 cytotoxicity according to ISO 10993-5
\n\u2022 Acute toxicity in the mouse according to ISO 10993-11
\n\u2022 irritation in rabbits according to ISO 10993-10
\n\u2022 sensitizing reaction in guinea pigs according to ISO 10993-10\u2026<\/p>\n
The ensemble ICARE, LEMI and PHYCHER Bio d\u00e9veloppement provides a technical answer to all biocompatibility tests, in particular, according to ISO 10993.
\nThe mission of ICARE through its services enables “Partner” clients to have the assurance that the device or product manufactured is placed on the market in compliance with regulatory and normative requirements.<\/p>\n
<\/p>\n
Laboratoires Icare<\/strong><\/span> With this new acquisition the Icare Group confirms its strategy of external growth and development of its service offer in a medical field deemed to be of strategic importance, given the evidence of the complementarity of the three structures to meet the needs of its clients and regulatory developments, in France and International. ICARE is […]<\/p>\n","protected":false},"author":2,"featured_media":1967,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-1971","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry"],"acf":[],"yoast_head":"\n
\nBiop\u00f4le Clermont-Limagne<\/strong><\/span>
\nPhone: +33 (0) 473 339 999
\nE-mail : accueil@laboratoiresicare.com<\/a>
\nWeb site : www.laboratoireicare.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"